Autologous hematopoietic cell transplantation for the treatment of relapsed/refractory pediatric, adolescent, and young adult hodgkin lymphoma: a single institutional experience

ABSTRACT Pediatric, adolescent, and young adult patients with relapsed or refractory Hodgkin lymphoma receive multimodal therapy, including autologous hematopoietic cell transplantation

(AutoHCT). Despite aggressive therapy, historical outcomes for this patient population have been poor. This paper describes a single institutional experience utilizing AutoHCT in 74 patients

treated from 1988–2015. Our results demonstrate significantly improved outcomes over time. Compared with patients treated in the earlier era (1988–2001), 5-year overall survival improved

from 62.5 ± 9.6% to 91.8 ± 4.4% (_p_ < 0.001) and event free survival improved from 41.7 ± 9.6% to 87.7 ± 5.3% (_I_ < 0.001) for patients treated in a later era (2002–2015).

Improvements in survival are multifactorial, including reductions in both relapse and nonrelapse mortality. Further investigation is needed to determine the role of AutoHCT in a modern

treatment cohort that includes frequent use of targeted immunotherapies. In addition, as the use and availability of effective novel therapeutics increases for this patient population there

may be an opportunity for the reduction of standard cytotoxic therapies, including in AutoHCT preparative regimens, thereby mitigating late effects. Access through your institution Buy or

subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12 print issues and online

access $259.00 per year only $21.58 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which

are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS

ALLOGENEIC TRANSPLANTATION AFTER PD-1 BLOCKADE FOR CLASSIC HODGKIN LYMPHOMA Article 03 March 2021 CLINICAL OUTCOMES OF RELAPSED AND REFRACTORY HODGKIN LYMPHOMA PATIENTS AFTER CONTEMPORARY

FIRST-LINE TREATMENT: A GERMAN HODGKIN STUDY GROUP ANALYSIS Article Open access 09 October 2021 THE OUTCOME OF PATIENTS WITH HODGKIN LYMPHOMA AND EARLY RELAPSE AFTER AUTOLOGOUS STEM CELL

TRANSPLANT HAS IMPROVED IN RECENT YEARS Article 12 April 2022 REFERENCES * Terezakis SA, Metzger ML, Hodgson DC, Schwartz CL, Advani R, Flowers CR, et al. ACR appropriateness criteria

pediatric Hodgkin Lymphoma. Pediatr Blood Cancer. 2014;61:1305–12. Article  Google Scholar  * Hoppe BS, Flampouri S, Zaiden R, Slayton W, Sandler E, Ozdemir S, et al. Involved-node proton

therapy in combined modality therapy for Hodgkin Lymphoma: results of a phase 2 study. Int J Radiat Oncol Biol Phys. 2014;89:1053–9. Article  Google Scholar  * Wolden SL, Chen L, Kelly KM,

Herzog P, Gilchrist GS, Thomson J, et al. Long-term results of CCG 5942: a randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin’s lymphoma—a report

from the Children’s Oncology Group. J Clin Oncol. 2012;30:3174–80. Article  Google Scholar  * Mauz-Korholz C, Metzger ML, Kelly KM, Schwartz CL, Castellanos ME, Dieckmann K, et al. Pediatric

Hodgkin Lymphoma. J Clin Oncol. 2015;33:2975–85. Article  Google Scholar  * Metzger ML, Hudson MM, Krasin MJ, Wu J, Kaste SC, Kun LE, et al. Initial response to salvage therapy determines

prognosis in relapsed pediatric Hodgkin lymphoma patients. Cancer. 2010;116:4376–84. Article  Google Scholar  * Hudson MM, Donaldson SS. Treatment of pediatric Hodgkin’s lymphoma. Semin

Hematol. 1999;36:313–23. CAS  PubMed  Google Scholar  * Friedmann AM, Wolfson JA, Hudson MM, Weinstein HJ, Link MP, Billett A, et al. Relapse after treatment of pediatric Hodgkin lymphoma:

outcome and role of surveillance after end of therapy. Pediatr Blood Cancer. 2013;60:1458–63. Article  Google Scholar  * Schellong G, Dorffel W, Claviez A, Korholz D, Mann G, Scheel-Walter

HG, et al. Salvage therapy of progressive and recurrent Hodgkin’s disease: results from a multicenter study of the pediatric DAL/GPOH-HD study group. J Clin Oncol. 2005;23:6181–9. Article 

Google Scholar  * Brockelmann PJ, Zagadailov EA, Corman SL, Chirikov V, Johnson C, Macahilig C, et al. Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are

Ineligible for autologous stem cell transplant: a Germany and United Kingdom retrospective study. Eur J Haematol. 2017;99:553–8. Article  Google Scholar  * Metzger ML, Mauz-Korholz C.

Epidemiology, outcome, targeted agents and immunotherapy in adolescent and young adult non-Hodgkin and Hodgkin lymphoma. Br J Haematol. 2019;185:1142–57. Article  Google Scholar  * von

Keudell G, Younes A. Novel therapeutic agents for relapsed classical Hodgkin lymphoma. Br J Haematol. 2019;184:105–12. Google Scholar  * Garfin PM, Link MP, Donaldson SS, Advani RH,

Luna-Fineman S, Kharbanda S, et al. Improved outcomes after autologous bone marrow transplantation for children with relapsed or refractory Hodgkin lymphoma: twenty years experience at a

single institution. Biol Blood Marrow Transpl. 2015;21:326–34. Article  Google Scholar  * Sumaili H, Al-Kofide A, Al-Seraihi A, Ayas M, Siddiqui K, El-Solh H, et al. Outcome of pediatric

patients with lymphoma following stem cell transplant: a single institution report. Leuk Lymphoma. 2015;56:1327–34. Article  CAS  Google Scholar  * Akhtar S, Rauf SM, Elhassan TA, Maghfoor

I. Outcome analysis of high-dose chemotherapy and autologous stem cell transplantation in adolescent and young adults with relapsed or refractory Hodgkin lymphoma. Ann Hematol.

2016;95:1521–35. Article  CAS  Google Scholar  * Satwani P, Ahn KW, Carreras J, Abdel-Azim H, Cairo MS, Cashen A, et al. A prognostic model predicting autologous transplantation outcomes in

children, adolescents and young adults with Hodgkin lymphoma. Bone Marrow Transplant. 2015;50:1416–23. Article  CAS  Google Scholar  * Verdeguer A, Pardo N, Madero L, Martinez A, Bureo E,

Fernandez JM, et al. Autologous stem cell transplantation for advanced Hodgkin’s disease in children. Spanish group for BMT in children (GETMON), Spain. Bone Marrow Transplant. 2000;25:31–4.

Article  CAS  Google Scholar  * Baker KS, Gordon BG, Gross TG, Abromowitch MA, Lyden ER, Lynch JC, et al. Autologous hematopoietic stem-cell transplantation for relapsed or refractory

Hodgkin’s disease in children and adolescents. J Clin Oncol. 1999;17:825–31. Article  CAS  Google Scholar  * Daw S, Wynn R, Wallace H. Management of relapsed and refractory classical Hodgkin

lymphoma in children and adolescents. Br J Haematol. 2011;152:249–60. Article  Google Scholar  * Abdalla A, Hammad M, Hafez H, Zaghloul MS, Taha H, El-Hennawy G, et al. Outcome predictors

of autologous hematopoietic stem cell transplantation in children with relapsed and refractory Hodgkin lymphoma: Single-center experience in a lower-middle-income country. Pediatr

Transplant. 2019;23:e13531. Article  Google Scholar  * National Cancer Institute. Adolescents and Young Adults with Cancer. http://www.cancer.gov/types/aya. * Burns LJ, Daniels KA, McGlave

PB, Miller WJ, Ramsay NK, Kersey JH, et al. Autologous stem cell transplantation for refractory and relapsed Hodgkin’s disease: factors predictive of prolonged survival. Bone Marrow

Transplant. 1995;16:13–8. CAS  Google Scholar  * Crump M, Smith AM, Brandwein J, Couture F, Sherret H, Sutton DM, et al. High-dose etoposide and melphalan, and autologous bone marrow

transplantation for patients with advanced Hodgkin’s disease: importance of disease status at transplant. J Clin Oncol. 1993;11:704–11. Article  CAS  Google Scholar  * Moskowitz CH, Walewski

J, Nademanee A, Masszi T, Agura E, Holowiecki J, et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood.

2018;132:2639–42. Article  CAS  Google Scholar  * Ansell SM. Immunotherapy in Hodgkin Lymphoma: the road ahead. Trends Immunol. 2019;40:380–6. Article  CAS  Google Scholar  * Brockelmann PJ,

Borchmann P, Engert A. Current and future immunotherapeutic approaches in Hodgkin lymphoma. Leuk Lymphoma. 2016;57:2014–24. Article  Google Scholar  * Dahi PB, Moskowitz CH, Giralt SA,

Lazarus HM. Novel agents positively impact chemotherapy and transplantation in Hodgkin lymphoma. Expert Rev Hematol. 2019:12;255–64. Article  CAS  Google Scholar  * Flerlage JE, Metzger ML,

Bhakta N. The management of Hodgkin lymphoma in adolescents and young adults: burden of disease or burden of choice? Blood. 2018;132:376–84. Article  CAS  Google Scholar  * Hui L, von

Keudell G, Wang R, Zeidan AM, Gore SD, Ma X, et al. Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell

transplantation. Cancer. 2017;123:3763–71. Article  Google Scholar  * Hodgson DC, Gilbert ES, Dores GM, Schonfeld SJ, Lynch CF, Storm H, et al. Long-term solid cancer risk among 5-year

survivors of Hodgkin’s lymphoma. J Clin Oncol. 2007;25:1489–97. Article  Google Scholar  * Castellino SM, Geiger AM, Mertens AC, Leisenring WM, Tooze JA, Goodman P, et al. Morbidity and

mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood. 2011;117:1806–16. Article  CAS  Google Scholar  * Armstrong GT, Chen Y, Yasui

Y, Leisenring W, Gibson TM, Mertens AC, et al. Reduction in late mortality among 5-year survivors of childhood cancer. N Engl J Med. 2016;374:833–42. Article  CAS  Google Scholar  * Bhuller

KS, Zhang Y, Li D, Sehn LH, Goddard K, McBride ML, et al. Late mortality, secondary malignancy and hospitalisation in teenage and young adult survivors of Hodgkin lymphoma: report of the

Childhood/Adolescent/Young Adult Cancer Survivors Research Program and the BC Cancer Agency Centre for Lymphoid Cancer. Br J Haematol. 2016;172:757–68. Article  Google Scholar  * Pui CH,

Campana D, Pei D, Bowman WP, Sandlund JT, Kaste SC, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2009;360:2730–41. Article  CAS  Google

Scholar  * Ramos CA, Ballard B, Zhang H, Dakhova O, Gee AP, Mei Z, et al. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J Clin

Investig. 2017;127:3462–71. Article  Google Scholar  * Harker-Murray PD, Drachtman RA, Hodgson DC, Chauvenet AR, Kelly KM, Cole PD. Stratification of treatment intensity in relapsed

pediatric Hodgkin lymphoma. Pediatr Blood Cancer. 2014;61:579–86. Article  Google Scholar  * Tinkle CL, Williams NL, Wu H, Wu J, Kaste SC, Shulkin BL, et al. Treatment patterns and disease

outcomes for pediatric patients with refractory or recurrent Hodgkin lymphoma treated with curative-intent salvage radiotherapy. Radiother Oncol. 2019;134:89–95. Article  Google Scholar  *

Khurana A, Armand P, Ansell SM. Checkpoint inhibition therapy as possible frontline therapy for Hodgkin lymphoma. Leuk Lymphoma. 2020:1–12. [Epub ahead of print]. * Geoerger B, Kang HJ,

Yalon-Oren M, Marshall LV, Vezina C, Pappo A, et al. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or

lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial. Lancet Oncol. 2020;21:121–33. Article  CAS  Google Scholar  Download references ACKNOWLEDGEMENTS This

work was supported in part by the American Lebanese Syrian Associated Charities (ALSAC). AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Department of Bone Marrow Transplantation and Cellular

Therapy, St. Jude Children’s Research Hospital, Memphis, TN, USA Aimee C. Talleur, David R. Shook & Brandon M. Triplett * Department of Oncology, St. Jude Children’s Research Hospital,

Memphis, TN, USA Jamie E. Flerlage & Melissa M. Hudson * University of Wisconsin School of Medicine and Public Health, Madison, WI, USA Abigail M. Chilsen * Department of Biostatistics,

St. Jude Children’s Research Hospital, Memphis, TN, USA Cheng Cheng & Sujuan Huang Authors * Aimee C. Talleur View author publications You can also search for this author inPubMed Google

Scholar * Jamie E. Flerlage View author publications You can also search for this author inPubMed Google Scholar * David R. Shook View author publications You can also search for this

author inPubMed Google Scholar * Abigail M. Chilsen View author publications You can also search for this author inPubMed Google Scholar * Melissa M. Hudson View author publications You can

also search for this author inPubMed Google Scholar * Cheng Cheng View author publications You can also search for this author inPubMed Google Scholar * Sujuan Huang View author publications

You can also search for this author inPubMed Google Scholar * Brandon M. Triplett View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR

Correspondence to Aimee C. Talleur. ETHICS DECLARATIONS CONFLICT OF INTEREST The authors declare that they have no conflict of interest. ADDITIONAL INFORMATION PUBLISHER’S NOTE Springer

Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS

ARTICLE Talleur, A.C., Flerlage, J.E., Shook, D.R. _et al._ Autologous hematopoietic cell transplantation for the treatment of relapsed/refractory pediatric, adolescent, and young adult

Hodgkin lymphoma: a single institutional experience. _Bone Marrow Transplant_ 55, 1357–1366 (2020). https://doi.org/10.1038/s41409-020-0879-4 Download citation * Received: 21 October 2019 *

Revised: 16 March 2020 * Accepted: 18 March 2020 * Published: 09 April 2020 * Issue Date: July 2020 * DOI: https://doi.org/10.1038/s41409-020-0879-4 SHARE THIS ARTICLE Anyone you share the

following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer

Nature SharedIt content-sharing initiative